PD‐1 blockade may enhance the antitumor activity of autologous CAR‐T cells engineered to recognize EGFRvIII+, MGMT‐unmethylated glioblastomas that are poorly responsive to standard‐of‐care alkylating chemotherapy. This evidence concerns the gene MGMT and glioblastoma.